GH Research PLC — Investor Relations & Filings
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to developing therapies for psychiatric and neurological disorders. The company's pipeline is centered on its novel and proprietary mebufotenin (5-MeO-DMT) product candidates. Its lead program, GH001, is an inhaled formulation of mebufotenin being developed for treatment-resistant depression (TRD). Other clinical programs are exploring treatments for bipolar II disorder with a depressive episode and postpartum depression. The company aims to deliver therapies with faster onset of action, durable effects, and improved remission rates. GH Research owns a growing intellectual property portfolio related to mebufotenin's therapeutic applications, formulations, and manufacturing methods.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 6-K | 2026-05-21 | English | |
| 6-K | 2026-05-14 | English | |
| 424B5 | 2026-05-14 | English | |
| 6-K | 2026-05-14 | English | |
| 6-K - GH Research PLC (0001855129) (Filer) | 2026-05-13 | English | |
| 6-K - GH Research PLC (0001855129) (Filer) | 2026-05-13 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46729565 | 6-K | 2026-05-21 | English | ||
| 46257322 | 6-K | 2026-05-14 | English | ||
| 46028749 | 424B5 | 2026-05-14 | English | ||
| 45974635 | 6-K | 2026-05-14 | English | ||
| 45767036 | 6-K - GH Research PLC (0001855129) (Filer) | 2026-05-13 | English | ||
| 45554240 | 6-K - GH Research PLC (0001855129) (Filer) | 2026-05-13 | English | ||
| 38566840 | 424B5 - GH Research PLC (0001855129) (Filer) | 2026-04-29 | English | ||
| 33041100 | 6-K - GH Research PLC (0001855129) (Filer) | 2026-03-25 | English | ||
| 32083527 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 13427655 | 6-K | 2026-01-22 | English | ||
| 13427654 | 6-K | 2026-01-15 | English | ||
| 13427656 | 6-K | 2026-01-13 | English | ||
| 13427657 | 6-K | 2026-01-08 | English | ||
| 13427658 | 6-K | 2026-01-05 | English | ||
| 13427659 | 6-K | 2026-01-02 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for GH Research PLC, but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
IMV Inc.
Pioneering novel immunotherapies using the proprietary DPX®…
|
IMV | CA | Professional, scientific and te… |
|
INBIOGEN CO.,Ltd
A life sciences firm offering bioinformatics and data minin…
|
101140 | KR | Professional, scientific and te… |
|
Incannex Healthcare Inc.
A clinical-stage biopharma firm developing cannabinoid and …
|
IXHL | US | Professional, scientific and te… |
|
Indaptus Therapeutics, Inc.
Develops bacterial-based immunotherapies for cancer and vir…
|
INDP | US | Professional, scientific and te… |
|
InflaRx N.V.
Clinical-stage biopharmaceutical firm developing C5a/C5aR p…
|
IFRX | NL | Professional, scientific and te… |
|
Inhalation Sciences Sweden AB
Develops lab instruments and provides research for preclini…
|
ISAB | SE | Professional, scientific and te… |
|
Initiator Pharma A/S
Clinical-stage company developing drugs for central and per…
|
INIT | DK | Professional, scientific and te… |
|
Inmolecule Nanotech, S.A.
Develops nanoparticles from plant compounds for biomedical …
|
MLINA | ES | Professional, scientific and te… |
|
InNexus Biotechnology Inc.
Develops enhanced monoclonal antibodies and diagnostics usi…
|
IXSBF | CA | Professional, scientific and te… |
|
Inotiv, Inc.
A CRO providing nonclinical drug development services and r…
|
NOTV | US | Professional, scientific and te… |
GH Research PLC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32311/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32311 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32311 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32311 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32311}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for GH Research PLC (id: 32311)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.